Propanc Biopharma Produces Synthetic Recombinant Proenzymes for Cancer Therapy Targeting Advanced Solid Tumors

Propanc Biopharma, Inc. announced the successful production of synthetic recombinant proenzymes trypsinogen and chymotrypsinogen through the Proenzyme Optimization Project 1 (POP1) joint research and drug discovery program. The project was conducted in collaboration with the Universities of Jaén and Granada, Spain. The synthetic development of these proenzymes aims to create a backup clinical co..